Cargando…

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

A vailable tyrosine kinase inhibitors for chronic myeloid leukemia bind in an adenosine 5′-triphosphate-binding pocket and are affected by evolving mutations that confer resistance. Rebastinib was identified as a switch control inhibitor of BCR-ABL1 and FLT3 and may be active against resistant mutat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortes, Jorge, Talpaz, Moshe, Smith, Hedy P., Snyder, David S., Khoury, Jean, Bhalla, Kapil N., Pinilla-Ibarz, Javier, Larson, Richard, Mitchell, David, Wise, Scott C., Rutkoski, Thomas J., Smith, Bryan D., Flynn, Daniel L., Kantarjian, Hagop M., Rosen, Oliver, Van Etten, Richard A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394958/ https://www.ncbi.nlm.nih.gov/pubmed/27927766 http://dx.doi.org/10.3324/haematol.2016.152710

Ejemplares similares

Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy
por: Kadia, Tapan Mahendra, et al.
Publicado: (2019)

Suboptimal Responses in Chronic Myeloid Leukemia
por: Jabbour, Elias, et al.
Publicado: (2012)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

Dasatinib dose management for the treatment of chronic myeloid leukemia
por: Talpaz, Moshe, et al.
Publicado: (2018)

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2022)

P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA
por: Müller, Martin C., et al.
Publicado: (2023)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019)

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
por: George, Binsah, et al.
Publicado: (2021)

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
por: Briski, Robert, et al.
Publicado: (2023)

Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia
por: Khan, Maliha, et al.
Publicado: (2017)

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia
por: Van Etten, Richard A.
Publicado: (2007)

Management of chronic myeloid leukemia in 2023 – common ground and common sense
por: Senapati, Jayastu, et al.
Publicado: (2023)

A case report and case review: Chronic myeloid leukemia (CML) blast phase with myelomastocytic differentiation
por: Song, Jinming, et al.
Publicado: (2020)

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
por: Bidikian, Aram, et al.
Publicado: (2022)

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia
por: Tashakori, Mehrnoosh, et al.
Publicado: (2022)

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
por: Wang, Feng, et al.
Publicado: (2021)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis
por: Radich, Jerald P., et al.
Publicado: (2023)

Immunotherapy in Acute Myeloid Leukemia: Where We Stand
por: Isidori, Alessandro, et al.
Publicado: (2021)

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
por: Talpaz, M, et al.
Publicado: (2013)

Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
por: Akard, Luke, et al.
Publicado: (2015)

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
por: Yilmaz, Musa, et al.
Publicado: (2019)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

Cutaneous myeloid sarcoma associated with chronic myeloid leukemia
por: Vasconcelos, Erica Rodrigues de Araujo, et al.
Publicado: (2017)

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype
por: Samra, Bachar, et al.
Publicado: (2020)

Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia()()
por: Delaunay, Jacques, et al.
Publicado: (2013)

Differential regulation of myeloid leukemias by the bone marrow microenvironment
por: Krause, Daniela S., et al.
Publicado: (2013)

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma
por: Leahey, Ann-Marie, et al.
Publicado: (2021)

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
por: Ottmann, Oliver, et al.
Publicado: (2018)

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
por: Morita, Kiyomi, et al.
Publicado: (2020)

Acute Myeloid Leukemia
Publicado: (2019)

Acute myeloid leukemia
por: Haferlach, Torsten
Publicado: (2019)

Chronic myeloid leukemia
por: Hantschel, Oliver
Publicado: (2019)

Acute myeloid leukemia
por: Ossenkoppele, Gert
Publicado: (2018)

Chronic myeloid leukemia
por: Sauβele, Susanne
Publicado: (2018)

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
por: Daver, Naval G., et al.
Publicado: (2022)

Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question
por: Jaramillo, Sonia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kge03qs8h199em2j31cb1ecsem